Cargando…

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 va...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Qian, Mao, Qunying, An, Chaoqiang, Zhang, Jialu, Gao, Fan, Bian, Lianlian, Li, Changgui, Liang, Zhenglun, Xu, Miao, Wang, Junzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009122/ https://www.ncbi.nlm.nih.gov/pubmed/33691606 http://dx.doi.org/10.1080/22221751.2021.1902245

Ejemplares similares

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
por: Zhang, Jialu, et al.
Publicado: (2021)

Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
por: He, Qian, et al.
Publicado: (2022)

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
por: He, Qian, et al.
Publicado: (2021)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
por: Bian, Lianlian, et al.
Publicado: (2021)

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
por: He, Qian, et al.
Publicado: (2022)

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates
por: Bai, Yu, et al.
Publicado: (2022)

Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
por: Zhang, Jialu, et al.
Publicado: (2022)

Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine
por: Gao, Fan, et al.
Publicado: (2022)

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
por: Mao, Qunying, et al.
Publicado: (2016)

Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC
por: Liang, Zhenglun, et al.
Publicado: (2014)

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
por: Pan, Yuting, et al.
Publicado: (2020)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

COVID-19 vaccines: progress and understanding on quality control and evaluation
por: Mao, Qunying, et al.
Publicado: (2021)

Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice
por: Bian, Lianlian, et al.
Publicado: (2022)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
por: Liu, Jianyang, et al.
Publicado: (2022)

A Short 5′triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I
por: Song, Ziyang, et al.
Publicado: (2022)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
por: Bian, Lianlian, et al.
Publicado: (2022)

Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8(+) T Cell Responses
por: Ring, Sandra S., et al.
Publicado: (2020)

Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques
por: Keelapang, Poonsook, et al.
Publicado: (2023)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Development of an ELISA Assay for the Determination of SARS-CoV-2 Protein Subunit Vaccine Antigen Content
por: Han, Lu, et al.
Publicado: (2022)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi
por: Sanchez Alberti, Andrés, et al.
Publicado: (2020)

Breaking Bottlenecks for the TCR Therapy of Cancer
por: Gaissmaier, Lena, et al.
Publicado: (2020)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
por: Li, Chong, et al.
Publicado: (2020)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3
por: Chen, Pan, et al.
Publicado: (2016)

A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine
por: Bai, Yu, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine
por: Liu, Dong, et al.
Publicado: (2022)

Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination
por: Vasconcelos, José R., et al.
Publicado: (2012)

Heterologous Boosting With Listeria-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection
por: Liu, Si-Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_55kccii7srr074gso4bladp88i